Quote of the week:
“When I used to see a patient who had been admitted to the emergency room, "[the medical specialist] said, "I would read an account of what the patient had said and done and what the doctor thought. Now what I get are the results of tests. I used to have a story, an understanding. Sometimes I can't figure out what happened to the patient. I think medicine has lost the narrative.”
— Nora Gallagher
DALLAS. (Ivanhoe Newswire) — Coronary artery disease affects 15 million Americans and remains the leading cause of death, killing more than 610,000 annually. The FDA has approved a new type of stent that dissolves over time, and gives doctors more life-saving options.
|
|
CHICAGO. (Ivanhoe Newswire) — Osteoarthritis is the most common form of arthritis in the U.S., affecting nearly 27 million adults. It is currently an incurable disease in which the joints deteriorate. Now, a therapy that has been used in eye surgery and to heal the skin of burn victims is being used for the first time in knees. This new form of treatment involves stem cells from amniotic fluid.
|
|
FORT LAUDERDALE, Fla. (Ivanhoe Newswire) — For people with life-threatening food allergies the Epi-Pen is the first line of treatment. The price of the pen has gone sky high- retailing at more than $600 for a pack of two in New York City. But what if a pill could one day replace the needle?
|
|
PITTSBURGH, Pa. (Ivanhoe Newswire) — Every year, surgeons use balloons and stents to open the arteries of nearly one million Americans. For about ten percent of those patients, the arteries will re-narrow meaning additional procedures. In some cases, doctors are using a small dose of a common cancer treatment to keep those arteries clear.
|
|
LOS ANGELES. (Ivanhoe Newswire) — Americans spend between one and four billion dollars a year treating hair loss. Now, four surgeons in the U.S. are testing a stem cell treatment in a non-surgical procedure. Overseas trials in Japan and Egypt are already showing some success.
|
|
.png)
No hay comentarios:
Publicar un comentario